DHX36

Across TCGA pan-cancer cohorts, DHX36 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHX36 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher DHX36 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DHX36 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, HNSC, and PRAD are the cancer types where DHX36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.201	0.740	.003	6	view →
HNSC	OS	Median	All	0.191	0.710	.021	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.219	0.702	.013	3	view →
UCEC	DFS	Median	All	0.929	0.625	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHX36–CHOL (OS)

Open the CHOL breakdown →